A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 03 Jun 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.